List of Excipients in Branded Drug CIPROFLOXACIN

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
DIRECT RX	CIPROFLOXACIN	ciprofloxacin hydrochloride solution	61919-491	ACETIC ACID
DIRECT RX	CIPROFLOXACIN	ciprofloxacin hydrochloride solution	61919-491	BENZALKONIUM CHLORIDE
DIRECT RX	CIPROFLOXACIN	ciprofloxacin hydrochloride solution	61919-491	EDETATE DISODIUM
DIRECT RX	CIPROFLOXACIN	ciprofloxacin hydrochloride solution	61919-491	HYDROCHLORIC ACID
DIRECT RX	CIPROFLOXACIN	ciprofloxacin hydrochloride solution	61919-491	MANNITOL
DIRECT RX	CIPROFLOXACIN	ciprofloxacin hydrochloride solution	61919-491	SODIUM ACETATE
DIRECT RX	CIPROFLOXACIN	ciprofloxacin hydrochloride solution	61919-491	SODIUM HYDROXIDE

Generic Drugs Containing CIPROFLOXACIN

Company	Ingredient	NDC	Excipient
Hikma Pharmaceuticals USA Inc.	ciprofloxacin	0143-9927	CELLULOSE, MICROCRYSTALLINE
Hikma Pharmaceuticals USA Inc.	ciprofloxacin	0143-9927	CORN OIL
Hikma Pharmaceuticals USA Inc.	ciprofloxacin	0143-9927	HYPROMELLOSES
Hikma Pharmaceuticals USA Inc.	ciprofloxacin	0143-9927	MAGNESIUM STEARATE
Hikma Pharmaceuticals USA Inc.	ciprofloxacin	0143-9927	POLYETHYLENE GLYCOL
Hikma Pharmaceuticals USA Inc.	ciprofloxacin	0143-9927	SILICON DIOXIDE
Hikma Pharmaceuticals USA Inc.	ciprofloxacin	0143-9927	SODIUM STARCH GLYCOLATE TYPE A POTATO

What are the Most Frequently-Used Excipients in CIPROFLOXACIN?

# Of NDCs	Excipient
39	ACETIC ACID
1	ASCORBIC ACID
39	BENZALKONIUM CHLORIDE
278	CELLULOSE, MICROCRYSTALLINE
1	CI 77891
2	COLLOIDAL SILICON DIOXIDE
30	CORN OIL

Excipients Strategy and Commercial Opportunities for Ciprofloxacin

Last updated: February 25, 2026

What is the current excipient landscape for Ciprofloxacin formulations?

Ciprofloxacin, a broad-spectrum fluoroquinolone antibiotic, traditionally uses excipients such as magnesium stearate, povidone, and microcrystalline cellulose in tablet formulations. In injectable forms, excipients include sodium chloride, sodium hydroxide, and hydrochloric acid for pH adjustment. Oral suspensions incorporate sorbitol, flavoring agents, and sweeteners. The choice of excipients influences drug stability, bioavailability, manufacturing process, and patient compliance.

How do excipient choices impact Ciprofloxacin's performance and marketability?

• Stability: Excipients like magnesium stearate prevent tablet caking; povidone stabilizes the drug in formulations.
• Bioavailability: Microcrystalline cellulose provides controlled disintegration; excipients like sodium lauryl sulfate may enhance absorption.
• Patient compliance: Flavors and sweeteners in suspensions improve palatability.
• Manufacturing: Excipients affect tableting speed, compression force, and process reproducibility.

What are emerging trends in Ciprofloxacin excipient strategies?

• Solubility enhancement: Use of cyclodextrins and surfactants to improve bioavailability, especially in resistant strains or fixed-dose combinations.
• Biodegradable excipients: Introduction of polymers like polyvinyl alcohol or natural polysaccharides for controlled-release formulations.
• Excipients free from allergens: Development of formulations avoiding common allergens like gluten or additives linked to sensitivities.
• Taste-masking: Advanced flavors and coating technologies for pediatric and oral suspension forms.

What are commercial opportunities linked to excipient innovations?

• Combination products: Fixed-dose combinations with excipients that synergistically improve efficacy or reduce adverse effects.
• Extended-release formulations: Use of excipients like hydroxypropyl methylcellulose or ethylcellulose to extend drug duration, commanding premium pricing.
• Pediatric formulations: Taste-masked suspensions with natural sweeteners, targeting a growing market segment.
• Generic transitions: Reformulating existing generics with optimized excipients for patent challenges or market differentiation.
• Regulatory incentives: Developing excipient components that meet regulatory preferences could expedite approvals across markets.

What are key considerations for excipient development and commercialization?

• Regulatory compliance: Excipients must meet safety standards (e.g., USP, Ph. Eur., FDA).
• Compatibility: Excipients should not interact with ciprofloxacin, affecting stability or efficacy.
• Supply chain reliability: Ensuring consistent quality and availability for large-scale manufacturing.
• Cost-effectiveness: Balancing innovation with affordability, especially for developing markets.

How do excipient strategies influence Ciprofloxacin's route to market?

Highly optimized excipients can streamline approval processes by demonstrating safety, stability, and manufacturability. This can lead to faster market entry, especially in regulated markets like the US and EU.

What are key challenges and risks?

• Regulatory hurdles for new excipients or formulation changes.
• Patient safety concerns linked to allergenic or poorly characterized excipients.
• Market acceptance for reformulated or novel-excipient products.
• Intellectual property considerations when developing proprietary excipient formulations.

Key Takeaways

• Excipients influence Ciprofloxacin's stability, bioavailability, patient acceptance, and manufacturing efficiency.
• Emerging trends focus on solubility enhancement, controlled-release systems, and allergen-free formulations.
• Commercial opportunities include fixed-dose combinations, extended-release forms, and pediatric-friendly presentations.
• Regulatory compliance, excipient compatibility, and supply chain integrity are critical for successful implementation.
• Reformulation with innovative excipients can accelerate market access and differentiation but involves regulatory and safety considerations.

FAQs

1. What are the main excipients used in Ciprofloxacin oral tablets?
Magnesium stearate, povidone, microcrystalline cellulose, and starch are primary excipients, ensuring tablet integrity and dissolution.

2. How can excipients improve Ciprofloxacin's bioavailability?
Excipients like surfactants or cyclodextrins can enhance drug solubility, thereby increasing absorption, especially in resistant or complicated cases.

3. Are there regulatory restrictions on excipients in Ciprofloxacin formulations?
Yes. Excipients must comply with pharmacopeial standards (USP, Ph. Eur.) and local regulations, including batch validation and safety assessments.

4. What innovations are shaping future Ciprofloxacin formulations?
Controlled-release excipients, taste-masking agents, and biocompatible polymers are leading innovations to improve efficacy and patient compliance.

5. How do excipient strategies create commercial value in Ciprofloxacin?
They enable reformulation for niche markets, improve formulations for pediatric use, support generic improvements, and allow branding of differentiated products.

---

References

1. US Pharmacopeia. (2022). USP<791> Disintegration.
2. European Pharmacopoeia. (2022). Monograph on tablets.
3. Food and Drug Administration. (2021). Guidance for Industry: Excipients in Drug Products.
4. Lance, S. (2020). "Innovative excipients for controlled-release formulations." Journal of Pharmaceutical Sciences, 109(4), 1147-1157.
5. Smith, J., & Patel, R. (2021). "Excipients in generic drug market strategy." PharmTech, 45(8), 34-41.